TürkiyeSGK and reimbursement
SGK adds a drug for a rare disease affecting the optic nerve to reimbursement
A statement by a ministry, institution or international organisation, or a change in regulations. It is not evidence about how well a treatment works.
A drug used for a rare disease affecting the optic nerve has been added to reimbursement coverage. The decision came through an amendment to the Sağlık Uygulama Tebliği (SUT, Health Implementation Communiqué). The amendment was published in the Resmî Gazete (Official Gazette) on October 2, 2026. Minister Işıkhan's statement did not name the disease or the drug. The same regulation also added advanced-technology surgical procedures for newborns and children to coverage.
What does it mean for patients and families?
Some patients are being followed for a rare disease that affects the optic nerve. These patients can ask their eye doctor (ophthalmologist) whether the new coverage applies to them.
Source
Memurlar.net: Bakan Işıkhan duyurdu: 2 ilaç daha geri ödeme kapsamına alındı
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.